Biohaven Ltd. reports the FDA instructed it to pause new opakalim enrollment under a September 4, 2026 partial clinical hold; BHV-1300 entered Phase 3, while BHV-1400 Phase 3 initiation is planned for 2026.
BHVN · Biohaven Ltd. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Biohaven's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia was accepted for review by the FDA, with a user fee goal date in the first quarter of 2027. The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026.
In August 2026, Biohaven agreed to license its Kv7 ion channel platform, including BHV-7000, worldwide to SK Biopharmaceuticals. SKBP will pay a non-creditable and non-refundable upfront fee of $400.0 million, $350.0 million at Closing and $50.0 million one year later, plus up to $150.0 million in milestones. An FDA partial clinical hold dated September 4, 2026 pauses new patient enrollment pending additional metabolite nonclinical data.
Biohaven said the FDA accepted its troriluzole resubmission for spinocerebellar ataxia and set a user fee goal date in the first quarter of 2027. The FDA considers the resubmission a complete response to the November 4, 2025 action letter.
Biohaven entered a Collaboration and License Agreement with Ono Pharmaceutical granting Ono an exclusive, royalty-bearing license to its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and ASEAN countries. Ono will pay an $80 million upfront payment at closing and another $20 million upon a milestone achievement, plus royalties of approximately 20% on net sales. Biohaven keeps rights outside the territory, including the United States, Europe and China.